6 April 2021 ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai
29 March 2021 ORYZON enrolls first patient in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
24 March 2021 ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal
15 March 2021 ORYZON announces successful pre-IND meeting with FDA for the clinical development of vafidemstat in Borderline Personality Disorder
9 March 2021 ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference
22 February 2021 ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020
11 February 2021 ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia
10 February 2021 ORYZON to present new clinical data and corporate updates at conferences in February and March
4 January 2021 ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021